Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.38 |
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874571 | 0.84 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4CNPC1 | |
| SCHEMBL6870169 | 0.78 | CSF1R (0.41) | CSF1RMEN1KMT2A | |
| SCHEMBL5044212 | 0.78 | PDE4B (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5713571 | 0.76 | HCRTR2 (0.36) | RAB9AHTT | |
| SCHEMBL6875789 | 0.75 | HTT (0.39) | CSF1RPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6867755 | 0.74 | KMT2A (0.44) | CSF1RNPC1MEN1KMT2AHTT | |
| SCHEMBL6878390 | 0.74 | MAPT (0.40) | CSF1RPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3042604 | 0.71 | MAPT (0.52) | NPC1RAB9AMEN1KMT2AHTT | |
| SCHEMBL6878386 | 0.68 | EPHX1 (0.51) | MEN1KMT2A | |
| SCHEMBL6114258 | 0.68 | HPGD (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456188-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6713499-B2 | ADENOSINE RECEPTOR AGONIST | HOFFMAN-LA ROCHE INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030153566-A1 | 7-Amino-benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003053946-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153566-A1 | 7-Amino-benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | CSF1R 718/4885PDE4D 871/4885PDE4A 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.